correction.17 Jul 2021 21:51
Please ignore my comment about the link I posted earlier and Synairgen. I think the investment case for Synairgen is complex. It would relate to the cost of the treatment, who its suitable for - if approved - and the merits of Synairgen versus the 75 (and perhaps more) Covid therapeutics in development. The mistake, I have made - is to make the investment case for Synairgen based on Syn vs vaccines and Syn in relation to health policy. Syn vs all of the other therapeutics - that must be more telling. For all that I will hold Synairgen as its done well with regards to the US, Warp Speed and trials etc. But if I had spare cash I would be trading to de-risk my Synairgen investment.